Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab dose-ranging study in moderate-to-severe atopic dermatitis
NCT03100344Phase 2Completed
- Sponsor
- Galderma
- Start
- Jun 2017
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of nemolizumab in atopic dermatitis (AD), sponsored by Galderma. Started Jun 2017; status: completed.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03100344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03100344.